News & Information

Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has furthered its commitment to stem cell research, drug discovery and ADME/Toxicology by acquiring a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio. Sigma Life Science, leveraging its zinc finger protein platform and stem cell technology portfolio, is now poised to develop a new set of differentiated tools for both the drug discovery and preclinical research communities. These tools will include novel iPS-cells, iPS-cell derived primary cells, novel assays, custom cell line development and ADME/Toxicology services. Under the terms of the agreement, iPS Academia Japan, Inc. (AJ) will receive a license fee from Sigma-Aldrich.

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.

Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it has signed a five-year contract extension with Honeywell for the manufacture and supply of Riedel-de Haën® high purity solvents, Karl Fischer reagents and other laboratory chemicals produced at Honeywell's Seelze, Germany, manufacturing site. The contract extends an existing supply agreement, in place since 1999, through March 31, 2019